We describe a case of a 77-year-old male who underwent transcatheter aortic valve implantation (TAVR) with Edwards SAPIEN XT size 26 mm for severe aortic stenosis. Postprocedural transesophageal echocardiography (TEE) showed left-to-right shunt between the left ventricular outflow tract just below the bioprosthesis and the right atrium across the atrioventricular septum (Gerbode defect). Three-dimensional echocardiography (3DE) allowed a detailed anatomical imaging of the shape and the location of a small, circular, atrioventricular defect that was a type II, direct, supravalvular, Gerbode-type defect. This is the third report of a Gerbode defect after TAVR whose diagnosis has important implications on clinical decision-making. TEE plays a key role; its diagnostic ability is enriched by the additional value of 3DE.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450239 | PMC |
| http://dx.doi.org/10.4103/jcecho.jcecho_56_18 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circular Shunt: A Loop Not to Be Ignored.
J Cardiothorac Vasc Anesth
December 2024
Department of Cardiothoracic Surgery, National Heart Center, Royal Hospital, Muscat, Oman.
A circular shunt, initially described by Shone et al. in 1962, refers to abnormal blood recirculation through complete intracardiac or intra- and extracardiac communications, bypassing the capillary beds. This pathophysiological condition is most commonly associated with complex congenital heart defects, such as Ebstein's malformation, pulmonary atresia, Gerbode defect, and so on.
View Article and Find Full Text PDFHemolytic anemia after percutaneous coronary intervention (PCI): A case report.
Heliyon
November 2024
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, PR China.
Background: In clinical practice, intravascular hemolysis is not common after interventional cardiovascular procedures. Although diagnostic and treatment techniques have developed, with the increasing importance placed on people's own health and the popularity of cardiovascular intervention, there have been occasional reports of hemolysis after different cardiovascular interventions, mainly including cardiac pacemaker implantation, atrial-fibrillation radiofrequency ablation, transcatheter aortic-valve implantation (TAVI), transcatheter mitral valve replacement (TMVR) and percutaneous repair of Gerbode defect and percutaneous coronary intervention (PCI) with Impella. However, so far, there have been no relevant reports on postoperative hemolysis after percutaneous coronary intervention (PCI).
View Article and Find Full Text PDFA case report of Ebstein's anomaly-Gerbode defect dyad: is there room for another anomaly in the same patient?
Eur Heart J Case Rep
September 2024
Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 5th Dept. of Internal Medicine, Medical Clinic No.1, 40006 Cluj-Napoca, Romania.
Article Synopsis
- - Ebstein's anomaly is a rare heart condition where the tricuspid valve is positioned unusually low in the heart and is often linked to other heart defects.
- - A case involving a 50-something man with Ebstein's anomaly and a rare combination with a septal defect (Gerbode defect) was discovered through MRI, along with an unusual origin of his right coronary artery.
- - Despite having several congenital issues, the patient had few symptoms until developing atrial flutter, which was successfully treated with catheter ablation, highlighting the importance of advanced imaging for diagnosis.
Off-label uses of the Amplatzer Piccolo Occluder in children with congenital and acquired heart diseases.
Future Cardiol
October 2024
Department of Pediatrics, Division of Cardiology, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, TN, USA.
The Amplatzer Piccolo Occluder (APO) is approved for patent ductus arteriosus (PDA) occlusion in infants weighing >700 g but could offer versatility to treat other lesions. Retrospective review of children in whom APO was utilized for defects other than PDA between January 2022 and June 2023. The APO was used in nine patients; three for ventricular septal defects, four with coronary fistulas, one for a ventricular pseudoaneurysm and one where APO deployed within a fenestration of a previously placed Amplatzer Septal Occluder.
View Article and Find Full Text PDFProcedural outcomes of percutaneous closure of perimembranous and other ventricular septal defects using Konar-MF occluder and short-term follow-up.
Ann Pediatr Cardiol
July 2024
Department of Pediatric Cardiac Intensive Care, NH-Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, West Bengal, India.
Introduction: The study aims to assess the procedural outcomes and follow-up after transcatheter closure of ventricular septal defects (VSDs) in children utilizing the Konar-MF™ occluder (Lifetech Scientific, Shenzhen, PRC) device.
Materials And Methods: Clinical features, demographic characteristics, and follow-up findings of children undergoing percutaneous VSD device closure were retrospectively analyzed from the medical records.
Results: Fifty-seven patients underwent VSD closure using the Konar-MF occluder between January 2019 and April 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!